Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.08 -0.02 (-1.82%) Market Cap: 276.01 Mil Enterprise Value: 161.16 Mil PE Ratio: 0 PB Ratio: 11.58 GF Score: 70/100

Adaptimmune Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript

Apr 17, 2023 / 01:30PM GMT
Release Date Price: $1.39 (+2.21%)
Gil Blum
Needham & Company, LLC - Analyst

Good morning, everyone. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today Adaptimmune's management team. And as a reminder, any viewers who are watching through our conference portal are able to submit questions via the ask-a-question box below the video feed window.

And with that, Adrian, please go ahead.

Adrian Rawcliffe
Adaptimmune Therapeutics plc - CEO

Thanks, Gil. Delighted to be able to introduce you all to Adaptimmune. If I can get the next slide, which is our disclaimer, which you can read on the website and move through to the subsequent slide. 3. Adaptimmune is a engineered T-cell therapy company with a particular focus on solid tumors, which puts us as differentiated with the majority of the currently marketed cell therapies in the oncology space. Specifically, our platform enable us to engineer the T-cell receptor, which is critical for enabling our engineered T cells to attack a range of solid tumors both with small

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot